{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:52:28Z","timestamp":1776095548943,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21J12535"],"award-info":[{"award-number":["21J12535"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02191"],"award-info":[{"award-number":["24K02191"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11095-026-04030-6","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:59:24Z","timestamp":1771977564000},"page":"693-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative Analysis of the Effect of Gastrointestinal Water Dynamics on Oral Drug Absorption using a Physiologically Based Integrated Liquid and Intestinal Absorption Drug (ILIAD) Pharmacokinetic Model"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-6660","authenticated-orcid":false,"given":"Satoru","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikumi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-7449","authenticated-orcid":false,"given":"Yoshiyuki","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0378-5173(89)90069-0","volume":"51","author":"RJ Hintz","year":"1989","unstructured":"Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51(1):9\u201317.","journal-title":"Int J Pharm"},{"issue":"9","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.xphs.2017.04.030","volume":"106","author":"K Ichijo","year":"2017","unstructured":"Ichijo K, Oda R, Ishihara M, Okada R, Moteki Y, Funai Y, et al. Osmolality of orally administered solutions influences luminal water volume and drug absorption in intestine. J Pharm Sci. 2017;106(9):2889\u201394.","journal-title":"J Pharm Sci"},{"issue":"4","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.118.084483","volume":"47","author":"Y Funai","year":"2019","unstructured":"Funai Y, Shirasaka Y, Ishihara M, Takemura M, Ichijo K, Kishimoto H, et al. Effect of Osmolality on the Pharmacokinetic Interaction Between Apple Juice and Atenolol in Rats. Drug Metab Dispos. 2019;47(4):386\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1248\/bpb.b23-00490","volume":"47","author":"M Takemura","year":"2024","unstructured":"Takemura M, Inoue K, Tamai I, Shirasaka Y. Magnitude of fruit juice-drug interactions due to osmolality-dependent fluid secretion: differences among Apple, Orange, and Grapefruit juices. Biol Pharm Bull. 2024;47(1):72\u20138.","journal-title":"Biol Pharm Bull"},{"key":"4030_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106136","volume":"172","author":"Y Funai","year":"2022","unstructured":"Funai Y, Takemura M, Inoue K, Shirasaka Y. Effect of ingested fluid volume and solution osmolality on intestinal drug absorption: impact on drug interaction with beverages. Eur J Pharm Sci. 2022;172: 106136.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4030_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/jps.2600660423","volume":"66","author":"PG Welling","year":"1977","unstructured":"Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci. 1977;66(4):549\u201352.","journal-title":"J Pharm Sci"},{"issue":"4","key":"4030_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejps.2004.11.005","volume":"24","author":"VH Sunesen","year":"2005","unstructured":"Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, M\u00fcllertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005;24(4):297\u2013303.","journal-title":"Eur J Pharm Sci"},{"key":"4030_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-8-5","volume":"8","author":"MA Karsdal","year":"2008","unstructured":"Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon calcitonin. BMC Clin Pharmacol. 2008;8: 5.","journal-title":"BMC Clin Pharmacol"},{"issue":"1","key":"4030_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2125.2012.04324.x","volume":"75","author":"H Jeon","year":"2013","unstructured":"Jeon H, Jang IJ, Lee S, Ohashi K, Kotegawa T, Ieiri I, et al. Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol. 2013;75(1):172\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4030_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-021-00212-z","volume":"7","author":"M Takemura","year":"2021","unstructured":"Takemura M, Tanaka Y, Inoue K, Tamai I, Shirasaka Y. Influence of osmolality on gastrointestinal fluid volume and drug absorption: potential impact on oral salt supplementation. J Pharm Healthc Sci. 2021;7(1): 29.","journal-title":"J Pharm Healthc Sci"},{"issue":"2","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","volume":"186","author":"LX Yu","year":"1999","unstructured":"Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119\u201325.","journal-title":"Int J Pharm"},{"issue":"Suppl 1","key":"4030_CR12","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","volume":"50","author":"B Agoram","year":"2001","unstructured":"Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1):S41-67.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4030_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337.","journal-title":"AAPS J"},{"issue":"4","key":"4030_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ejps.2013.05.019","volume":"49","author":"E Sj\u00f6gren","year":"2013","unstructured":"Sj\u00f6gren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennern\u00e4s H, et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49(4):679\u201398.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4030_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1124\/dmd.114.060038","volume":"43","author":"H Ando","year":"2015","unstructured":"Ando H, Hisaka A, Suzuki H. A new physiologically based pharmacokinetic model for the prediction of gastrointestinal drug absorption: translocation model. Drug Metab Dispos. 2015;43(4):590\u2013602.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-023-00809-2","volume":"25","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Inoue K, Tamai I, Shirasaka Y. Quantitative analysis of gastrointestinal water dynamics by means of a physiologically based fluid kinetic model. AAPS J. 2023;25(3):42.","journal-title":"AAPS J"},{"issue":"1","key":"4030_CR17","doi-asserted-by":"publisher","first-page":"17454","DOI":"10.1038\/s41598-023-44742-y","volume":"13","author":"Y Funai","year":"2023","unstructured":"Funai Y, Ichijo K, Suzuki S, Tateishi Y, Inoue K, Tamai I, et al. Quantitative analysis of gastrointestinal fluid absorption and secretion to estimate luminal fluid dynamics in rats. Sci Rep. 2023;13(1):17454.","journal-title":"Sci Rep"},{"issue":"5","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1023\/A:1023294632129","volume":"26","author":"A Hisaka","year":"1998","unstructured":"Hisaka A, Sugiyama Y. Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J Pharmacokinet Biopharm. 1998;26(5):495\u2013519.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"Part B","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"101057","DOI":"10.1016\/j.jddst.2019.05.006","volume":"56","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Shirasaka Y, Okada R, Eguchi A, Kishimoto H, Langguth P, et al. Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of P-glycoprotein substrate talinolol using physiologically based pharmacokinetic absorption model. J Drug Deliv Sci Technol. 2020;56(Part B):101057.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"4030_CR20","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1124\/dmd.111.040477","volume":"39","author":"Y Yabe","year":"2011","unstructured":"Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos. 2011;39(10):1808\u201314.","journal-title":"Drug Metab Dispos"},{"key":"4030_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejps.2014.04.008","volume":"61","author":"S Cviji\u0107","year":"2014","unstructured":"Cviji\u0107 S, Paroj\u010di\u0107 J, Langguth P. Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: in vitro experimental simulation and computational verification. Eur J Pharm Sci. 2014;61:40\u201353.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"4030_CR22","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1124\/dmd.116.070011","volume":"44","author":"J Takano","year":"2016","unstructured":"Takano J, Maeda K, Bolger MB, Sugiyama Y. The prediction of the relative importance of CYP3A\/P-glycoprotein to the nonlinear intestinal absorption of drugs by advanced compartmental absorption and transit model. Drug Metab Dispos. 2016;44(11):1808\u201318.","journal-title":"Drug Metab Dispos"},{"issue":"5-6","key":"4030_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/bdd.711","volume":"31","author":"T Uchimura","year":"2010","unstructured":"Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos. 2010;31(5\u20136):286\u201397.","journal-title":"Biopharm Drug Dispos"},{"key":"4030_CR24","unstructured":"Ranitidine hydrochloride (Zantac\u00ae) Japanese interview form information. Tokyo: GlaxoSmithKline K.K. https:\/\/image.packageinsert.jp\/pdf.php?mode=1&yjcode=2325002F1194."},{"issue":"8","key":"4030_CR25","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s11095-009-9902-6","volume":"26","author":"H Imawaka","year":"2009","unstructured":"Imawaka H, Ito K, Kitamura Y, Sugiyama K, Sugiyama Y. Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans. Pharm Res. 2009;26(8):1881\u20139.","journal-title":"Pharm Res"},{"issue":"9","key":"4030_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1124\/dmd.111.039248","volume":"39","author":"M Gertz","year":"2011","unstructured":"Gertz M, Houston JB, Galetin A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 2011;39(9):1633\u201342.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","volume":"13","author":"LZ Benet","year":"2011","unstructured":"Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519\u201347.","journal-title":"AAPS J"},{"issue":"7","key":"4030_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1124\/dmd.121.000361","volume":"49","author":"S Asano","year":"2021","unstructured":"Asano S, Yoshitomo A, Hozuki S, Sato H, Kazuki Y, Hisaka A. A new intestinal model for analysis of drug absorption and interactions considering physiological translocation of contents. Drug Metab Dispos. 2021;49(7):581\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"4030_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/dmd.110.032649","volume":"38","author":"M Gertz","year":"2010","unstructured":"Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4030_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0009-9236(96)90182-4","volume":"59","author":"T Gramatt\u00e9","year":"1996","unstructured":"Gramatt\u00e9 T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther. 1996;59(5):541\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4030_CR31","first-page":"72","volume":"50","author":"B Trausch","year":"1995","unstructured":"Trausch B, Oertel R, Richter K, Gramatt\u00e9 T. The protein binding of talinolol. Pharmazie. 1995;50(1):72.","journal-title":"Pharmazie"},{"issue":"5","key":"4030_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejps.2004.04.006","volume":"22","author":"CA Bergstr\u00f6m","year":"2004","unstructured":"Bergstr\u00f6m CA, Luthman K, Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharm Sci. 2004;22(5):387\u201398.","journal-title":"Eur J Pharm Sci"},{"key":"4030_CR33","unstructured":"Celiprolol hydrochloride (Selectol\u00ae) Japanese interview form information. Kyoto: Nippon Shinyaku Co., Ltd. https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/530263_2149029F1020_1_16F_1F.pdf."},{"key":"4030_CR34","unstructured":"Fexofenadine hydrochloride (Allegra\u00ae) Japanese interview form information. Tokyo: Sanofi K.K. https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/780069_4490023F1024_1_025_1F.pdf."},{"issue":"1","key":"4030_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/jps.21114","volume":"97","author":"Y Shirasaka","year":"2008","unstructured":"Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008;97(1):553\u201365.","journal-title":"J Pharm Sci"},{"issue":"12","key":"4030_CR36","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1021\/acs.molpharmaceut.7b00396","volume":"14","author":"B Hens","year":"2017","unstructured":"Hens B, Pathak SM, Mitra A, Patel N, Liu B, Patel S, et al. In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of Posaconazole. Mol Pharm. 2017;14(12):4321\u201333.","journal-title":"Mol Pharm"},{"issue":"3","key":"4030_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1517\/17425250902835506","volume":"5","author":"K Sugano","year":"2009","unstructured":"Sugano K. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2009;5(3):259\u201393.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"4030_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12249-019-1563-0","volume":"21","author":"M Chegireddy","year":"2020","unstructured":"Chegireddy M, Hanegave GK, Lakshman D, Urazov A, Sree KN, Lewis SA, et al. The Significance of Utilizing In Vitro Transfer Model and Media Selection to Study the Dissolution Performance of Weak Ionizable Bases: Investigation Using Saquinavir as a Model Drug. AAPS PharmSciTech. 2020;21(2):47.","journal-title":"AAPS PharmSciTech"},{"issue":"3-4","key":"4030_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ejps.2010.07.013","volume":"41","author":"SM Pathak","year":"2010","unstructured":"Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-preparation and in vitro and in vivo evaluation. Eur J Pharm Sci. 2010;41(3\u20134):440\u201351.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4030_CR40","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11095-014-1487-z","volume":"32","author":"JH Fagerberg","year":"2015","unstructured":"Fagerberg JH, Karlsson E, Ulander J, Hanisch G, Bergstr\u00f6m CA. Computational prediction of drug solubility in fasted simulated and aspirated human intestinal fluid. Pharm Res. 2015;32(2):578\u201389.","journal-title":"Pharm Res"},{"issue":"8","key":"4030_CR41","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s11095-006-9020-7","volume":"23","author":"M Tubic","year":"2006","unstructured":"Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res. 2006;23(8):1712\u201320.","journal-title":"Pharm Res"},{"issue":"10","key":"4030_CR42","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1021\/mp500330y","volume":"11","author":"M Drozdzik","year":"2014","unstructured":"Drozdzik M, Gr\u00f6er C, Penski J, Lapczuk J, Ostrowski M, Lai Y, et al. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm. 2014;11(10):3547\u201355.","journal-title":"Mol Pharm"},{"issue":"3","key":"4030_CR43","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","volume":"27","author":"T Tachibana","year":"2010","unstructured":"Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res. 2010;27(3):442\u20136.","journal-title":"Pharm Res"},{"issue":"12","key":"4030_CR44","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1124\/dmd.113.051664","volume":"41","author":"FH Karlsson","year":"2013","unstructured":"Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, Peters SA. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development. Drug Metab Dispos. 2013;41(12):2033\u201346.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"4030_CR45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/00498250902846252","volume":"39","author":"T Tachibana","year":"2009","unstructured":"Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009;39(6):430\u201343.","journal-title":"Xenobiotica"},{"issue":"2","key":"4030_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.1840090222","volume":"9","author":"HA Wynne","year":"1989","unstructured":"Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9(2):297\u2013301.","journal-title":"Hepatology"},{"issue":"4","key":"4030_CR47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpt1979254408","volume":"25","author":"WD Mason","year":"1979","unstructured":"Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979;25(4):408\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4030_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-198106050-00004","volume":"6","author":"CG Reg\u00e5rdh","year":"1981","unstructured":"Reg\u00e5rdh CG, Jord\u00f6 L, Ervik M, Lundborg P, Olsson R, R\u00f6nn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6(5):375\u201388.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4030_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1124\/dmd.119.089599","volume":"48","author":"M Yamada","year":"2020","unstructured":"Yamada M, Inoue SI, Sugiyama D, Nishiya Y, Ishizuka T, Watanabe A, et al. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models. Drug Metab Dispos. 2020;48(4):288\u201396.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4030_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1021\/jm901371v","volume":"53","author":"MV Varma","year":"2010","unstructured":"Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53(3):1098\u2013108.","journal-title":"J Med Chem"},{"issue":"1","key":"4030_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","volume":"58","author":"HH Kupferschmidt","year":"1995","unstructured":"Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Kr\u00e4henb\u00fchl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995;58(1):20\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4030_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00004714-199508000-00004","volume":"15","author":"PD Kroboth","year":"1995","unstructured":"Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J Clin Psychopharmacol. 1995;15(4):259\u201362.","journal-title":"J Clin Psychopharmacol"},{"key":"4030_CR53","doi-asserted-by":"crossref","unstructured":"Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;(Suppl 1):5S-12S.","DOI":"10.1046\/j.0306-5251.2001.00027.x"},{"key":"4030_CR54","unstructured":"Thummel KE, Shen DD, and Isoherranen N. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics, 13th edition. New York: McGraw Hill; 2017. p. 1325-1378."},{"issue":"5","key":"4030_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/bdd.2510160505","volume":"16","author":"B Trausch","year":"1995","unstructured":"Trausch B, Oertel R, Richter K, Gramatt\u00e9 T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos. 1995;16(5):403\u201314.","journal-title":"Biopharm Drug Dispos"},{"key":"4030_CR56","unstructured":"Hitzenberger VG, Takacs F, Pittner H. Pharmacokinetics of the \u03b2-Adrenergic Receptor Blocking Agent Celiprolol after Single Intravenous and Oral Administrations in Man. Arzneim.-Forsch.\/Drug Res. 1983;33(I), Nr. la.:50\u20132."},{"issue":"2","key":"4030_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","volume":"40","author":"G Lappin","year":"2010","unstructured":"Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40(2):125\u201331.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"4030_CR58","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1378\/chest.94.5.954","volume":"94","author":"RA Barbarash","year":"1988","unstructured":"Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988;94(5):954\u20139.","journal-title":"Chest"},{"issue":"4","key":"4030_CR59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1046\/j.1365-2125.1998.t01-1-00687.x","volume":"45","author":"HH Kupferschmidt","year":"1998","unstructured":"Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Kr\u00e4henb\u00fchl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45(4):355\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4030_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259\u201376.","journal-title":"J Pharm Sci"},{"issue":"6","key":"4030_CR61","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238\u201357.","journal-title":"J Pharm Sci"},{"issue":"4","key":"4030_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1067\/mcp.2000.109797","volume":"68","author":"K Westphal","year":"2000","unstructured":"Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug\/drug interaction. Clin Pharmacol Ther. 2000;68(4):345\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4030_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF00547375","volume":"29","author":"LD Bornemann","year":"1985","unstructured":"Bornemann LD, Min BH, Crews T, Rees MM, Blumenthal HP, Colburn WA, et al. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol. 1985;29(1):91\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"4030_CR64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1440-1681.2009.05285.x","volume":"37","author":"S Misaka","year":"2010","unstructured":"Misaka S, Uchida S, Imai H, Inui N, Nishio S, Ohashi K, et al. Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers. Clin Exp Pharmacol Physiol. 2010;37(3):290\u20135.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"4030_CR65","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/00005344-199512000-00005","volume":"26","author":"C de Mey","year":"1995","unstructured":"de Mey C, Schroeter V, Butzer R, Jahn P, Weisser K, Wetterich U, et al. Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. J Cardiovasc Pharmacol. 1995;26(6):879\u201388.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"4030_CR66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/clpt.2011.108","volume":"90","author":"K Maeda","year":"2011","unstructured":"Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther. 2011;90(2):263\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4030_CR67","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/jps.21010","volume":"97","author":"DA Volpe","year":"2008","unstructured":"Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2008;97(2):712\u201325.","journal-title":"J Pharm Sci"},{"key":"4030_CR68","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2016.12.027","volume":"114","author":"JB Lee","year":"2017","unstructured":"Lee JB, Zgair A, Taha DA, Zang X, Kagan L, Kim TH, et al. Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. Eur J Pharm Biopharm. 2017;114:38\u201342.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"4030_CR69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejps.2011.12.007","volume":"45","author":"ST Buckley","year":"2012","unstructured":"Buckley ST, Fischer SM, Fricker G, Brandl M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci. 2012;45(3):235\u201350.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"4030_CR70","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1023\/A:1010974909998","volume":"18","author":"I Behrens","year":"2001","unstructured":"Behrens I, Stenberg P, Artursson P, Kissel T. Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res. 2001;18(8):1138\u201345.","journal-title":"Pharm Res"},{"issue":"5","key":"4030_CR71","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1021\/js9701216","volume":"87","author":"RE Oliver","year":"1998","unstructured":"Oliver RE, Jones AF, Rowland M. What surface of the intestinal epithelium is effectively available to permeating drugs? J Pharm Sci. 1998;87(5):634\u20139.","journal-title":"J Pharm Sci"},{"key":"4030_CR72","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejps.2019.02.017","volume":"131","author":"AS Darwich","year":"2019","unstructured":"Darwich AS, Burt HJ, Rostami-Hodjegan A. The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. Eur J Pharm Sci. 2019;131:195\u2013207.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4030_CR73","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2133\/dmpk.DMPK-09-RG-038","volume":"25","author":"M Kato","year":"2010","unstructured":"Kato M, Chiba K, Ito T, Koue T, Sugiyama Y. Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab Pharmacokinet. 2010;25(4):367\u201378.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"12","key":"4030_CR74","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bcp.2005.09.011","volume":"70","author":"J M\u00fcller","year":"2005","unstructured":"M\u00fcller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005;70(12):1851\u201360.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4030_CR75","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/jpet.102.034140","volume":"302","author":"DS Wang","year":"2002","unstructured":"Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302(2):510\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"4030_CR76","first-page":"166","volume":"2","author":"Y Mimura","year":"2015","unstructured":"Mimura Y, Yasujima T, Ohta K, Inoue K, Yuasa H. Functional identification of organic cation transporter 1 as an atenolol transporter sensitive to flavonoids. Biochem Biophys Rep. 2015;2:166\u201371.","journal-title":"Biochem Biophys Rep"},{"issue":"12","key":"4030_CR77","doi-asserted-by":"publisher","first-page":"e0189521","DOI":"10.1371\/journal.pone.0189521","volume":"12","author":"MJ Meyer","year":"2017","unstructured":"Meyer MJ, Seitz T, Brockm\u00f6ller J, Tzvetkov MV. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS ONE. 2017;12(12):e0189521.","journal-title":"PLoS ONE"},{"issue":"1-2","key":"4030_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijpharm.2011.05.016","volume":"414","author":"M Kataoka","year":"2011","unstructured":"Kataoka M, Iwai K, Masaoka Y, Sakane T, Sakuma S, Yamashita S. Scale-up of in vitro permeation assay data to human intestinal permeability using pore theory. Int J Pharm. 2011;414(1\u20132):69\u201376.","journal-title":"Int J Pharm"},{"issue":"1","key":"4030_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1067\/mcp.2002.121152","volume":"71","author":"GK Dresser","year":"2002","unstructured":"Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4030_CR80","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/jpet.103.051300","volume":"306","author":"D Kobayashi","year":"2003","unstructured":"Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003;306(2):703\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"4030_CR81","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1021\/mp200026v","volume":"8","author":"X Ming","year":"2011","unstructured":"Ming X, Knight BM, Thakker DR. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm. 2011;8(5):1677\u201386.","journal-title":"Mol Pharm"},{"issue":"2","key":"4030_CR82","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.dmpk.2014.11.002","volume":"30","author":"Y Uchida","year":"2015","unstructured":"Uchida Y, Ohtsuki S, Kamiie J, Ohmine K, Iwase R, Terasaki T. Quantitative targeted absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured for 2, 3, and 4 weeks. Drug Metab Pharmacokinet. 2015;30(2):205\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"4030_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/bdd.2025","volume":"38","author":"S Br\u00fcck","year":"2017","unstructured":"Br\u00fcck S, Strohmeier J, Busch D, Drozdzik M, Oswald S. Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue. Biopharm Drug Dispos. 2017;38(2):115\u201326.","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"4030_CR84","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/BF00605630","volume":"16","author":"A Melander","year":"1979","unstructured":"Melander A, Stenberg P, Liedholm H, Scherst\u00e9n B, W\u00e5hlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol. 1979;16(5):327\u201330.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"4030_CR85","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.molpharmaceut.7b00919","volume":"15","author":"M Grimm","year":"2018","unstructured":"Grimm M, Koziolek M, Saleh M, Schneider F, Garbacz G, K\u00fchn JP, et al. Gastric emptying and small bowel water content after administration of Grapefruit juice compared to water and isocaloric solutions of Glucose and Fructose: a four-way crossover MRI pilot study in healthy subjects. Mol Pharm. 2018;15(2):548\u201359.","journal-title":"Mol Pharm"},{"key":"4030_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2022.100488","volume":"48","author":"A Kambayashi","year":"2023","unstructured":"Kambayashi A, Shirasaka Y. Food effects on gastrointestinal physiology and drug absorption. Drug Metab Pharmacokinet. 2023;48: 100488.","journal-title":"Drug Metab Pharmacokinet"},{"key":"4030_CR87","doi-asserted-by":"publisher","first-page":"102100","DOI":"10.1016\/j.jddst.2020.102100","volume":"60","author":"M Kataoka","year":"2020","unstructured":"Kataoka M, Morimoto S, Minami K, Higashino H, Nakano M, Tomita Y, et al. In vivo screening of oral formulations using rats: Effects of ingested water volume on oral absorption of BCS class I and III drugs from immediate-release formulations. J Drug Deliv Sci Technol. 2020;60:102100.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"4030_CR88","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1124\/dmd.118.081315","volume":"46","author":"T De Bruyn","year":"2018","unstructured":"De Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, et al. Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro-In Vivo Scaling of Hepatic Uptake Clearance. Drug Metab Dispos. 2018;46(7):989\u20131000.","journal-title":"Drug Metab Dispos"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04030-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:03:11Z","timestamp":1776092591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04030-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04030-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}